Truist lowered the firm’s price target on Genesco (GCO) to $32 from $38 and keeps a Hold rating on the shares after its “solid” Q4 results. The company’s Journeys group continues to generate strong momentum with premium product assortments fueling higher average sales prices and robust full-priced selling, though the firm remains cautious on the choppy macro, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GCO:
- Genesco Earnings Call Highlights Journeys-Led Momentum
- Morning Movers: Nutex Health sinks after fourth quarter results
- Options Volatility and Implied Earnings Moves Today, March 06, 2026
- Genesco reports Q4 adjusted EPS $3.74 vs. $3.26 last year
- Genesco sees FY27 adjusted EPS $1.90-$2.30, consensus $1.93